Close Menu
    Facebook X (Twitter) Instagram
    Latest
    • A new malpractice being observed: Reviewers asking their own papers to cite
    • 100% APC Waiver for Authors from “Group A” Category Countries Indicated by Research4Life
    • Retraction Notice: Pharmacological Actions of Impatiens
    • DOI Allocated and Activated for 281 Articles and Abstracts Published in the period of 2014-2017
    • IGJPS, 2021, Vol 11, Issue 3
    • IGJPS, 2021, Vol 11, Issue 2
    • IGJPS, 2021, Vol 11, Issue 1
    • Table of Contents, Vol 10, Issue 4
    INDO GLOBAL JOURNAL OF PHARMACEUTICAL SCIENCESINDO GLOBAL JOURNAL OF PHARMACEUTICAL SCIENCES
    • Home
    • About Us
    • Issues
      • IGJPS 2022 and Onwards
      • IGJPS, 2021, Vol 11, Issue 3
      • IGJPS, 2021, Vol 11, Issue 2
      • IGJPS, 2021, Vol 11, Issue 1
      • IGJPS, 2020, Vol 10, Issue 4
      • IGJPS, 2020, Vol 10, Issue 3
      • IGJPS, 2020, Vol 10, Issue 2
      • IGJPS, 2020, Vol 10, Issue 1
      • IGJPS, 2019, Vol 9, Issue 2 (Suppl.)
      • IGJPS, 2019, Vol 9, Issue 2
      • IGJPS, 2019, Vol 9, Issue 1
      • IGJPS, 2018, Vol 8, Issue 3
      • IGJPS, 2018, Vol 8, Issue 2
      • IGJPS, 2018, Vol 8, Issue 1
      • IGJPS, 2017, Vol 7, Issue 2
      • IGJPS, 2017, Vol 7, Issue 1
      • IGJPS, 2016, Vol 6, Issue 2
      • IGJPS, 2016, Vol 6, Issue 1
      • IGJPS, 2015, Vol 5, Issue 3
      • IGJPS, 2015, Vol 5, Issue 2
      • IGJPS, 2015, Vol 5, Issue 1
      • IGJPS, 2014, Vol 4, Issue 3
      • IGJPS, 2014, Vol 4, Issue 2
      • IGJPS, 2014, Vol4, Issue 1
      • IGJPS, 2013, Vol 3, Issue 3
      • IGJPS,2013, Vol 3, Issue 2
      • IGJPS, 2013, Vol 3, Issue 1
      • IGJPS, 2012, Vol 2, Issue 4
      • IGJPS, 2012, Vol 2, Issue 3
      • IGJPS, 2012, Vol 2, Issue 2
      • IGJPS, 2012, Vol 2, Issue 1
      • IGJPS, 2011, Vol 1, Issue 4
      • IGJPS, 2011, Vol 1, Issue 3
      • IGJPS, 2011, Vol 1, Issue 2
      • IGJPS, 2011, Vol 1, Issue 1
    • Editorial Board
    • Guidelines For Authors
    • Indexed
    • Manuscript Submission
    • Contact Us
    INDO GLOBAL JOURNAL OF PHARMACEUTICAL SCIENCESINDO GLOBAL JOURNAL OF PHARMACEUTICAL SCIENCES
    You are at:Home»News»FDA approves Voraxaze to treat patients with toxic methotrexate levels

    FDA approves Voraxaze to treat patients with toxic methotrexate levels

    0
    By Rajeev Singla on January 23, 2012 News

    The U.S. Food and Drug Administration today approved Voraxaze (glucarpidase) to treat patients with toxic levels of methotrexate in their blood due to kidney failure.

    Methotrexate is a commonly used cancer chemotherapy drug normally eliminated from the body by the kidneys. However, patients receiving high doses of methotrexate may develop kidney failure.

    Voraxaze is an enzyme that rapidly reduces methotrexate levels by breaking the chemotherapy drug down to a form that can be eliminated from the body. Voraxaze is administered directly into a patient’s vein (intravenously).

    “Prolonged exposure to high levels of methotrexate can result in kidney and liver damage, severe mouth sores, damage to the lining of the intestine, skin rashes, and death due to low blood counts,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Voraxaze is an important new treatment option for cancer patients aimed at preventing these toxicities associated with sustained high levels of methotrexate.”

    Voraxaze has an orphan drug designation, given to therapies indicated for rare or specific disease populations.

    A single clinical study of 22 patients evaluated the effectiveness of Voraxaze. All patients received Voraxaze treatment. The study considered treatment a success if the methotrexate level fell below a critical level within 15 minutes and stayed below the critical level for eight days. Ten of the 22 patients achieved this standard. Although not all patients experienced this result, Voraxaze eliminated 95 percent of the methotrexate in all patients.

    A separate clinical study evaluated the safety of Voraxaze in 290 patients experiencing problems clearing methotrexate from their blood.

    The most common side effects observed in greater than one percent of patients in the clinical study were low blood pressure (hypotension), headache, nausea, vomiting, flushing, and abnormal sensation (paraesthesia).

    Voraxaze is marketed by BTG International Inc., West Conshohocken, Pa.

     

     

    Source: US FDA

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    A new malpractice being observed: Reviewers asking their own papers to cite

    100% APC Waiver for Authors from “Group A” Category Countries Indicated by Research4Life

    Retraction Notice: Pharmacological Actions of Impatiens

    Comments are closed.

    Latest News
    A new malpractice being observed: Reviewers asking their own papers to cite
    ...
    100% APC Waiver for Authors from “Group A” Category Countries Indicated by Research4Life
    ...
    Retraction Notice: Pharmacological Actions of Impatiens
    ...
    DOI Allocated and Activated for 281 Articles and Abstracts Published in the period of 2014-2017
    ...
    Top Peer Reviewer as New Associate Editor: Dr. Ghulam Md. Ashraf, King Abdulaziz University, Jeddah, Saudi Arabia
    ...
    Highly Cited Articles

    Microencapsulation–A Novel Approach in Drug Delivery: A Review

    Review on the pharmacognostical & pharmacological characterization of Apium graveolens Linn


    Medicinal Plants of Rural India: A Review of Use by Indian Folks


    Self Emulsifying Drug Delivery System: A Tool in Solubility Enhancement of Poorly Soluble Drugs


    Antioxidant and antimicrobial activities of Cocos nucifera Linn.(Arecaceae) endocarp extracts

    Impotant Links
    • About Us
    • Call For Papers
    • Contact Us
    • Editorial Board
    • For Reviewers
    • Guidelines For Authors
    • Home Page
    • Indexed
    • Issues
    • Manuscript Submission
    • Checkout
    • Transaction Results
    • Your Account
    Sponsored
    Copyright © 2011 iGlobal Research & Publishing Foundation
    Powered By :- Ganga Graphix.

    Type above and press Enter to search. Press Esc to cancel.